Top

Published in:

01-04-2018 | Original Article

Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy

Authors: Chih-Yang Huang, Shu-Fen Chiang, Tao-Wei Ke, Tsung-Wei Chen, Yu-Ching Lan, Ying-Shu You, An-Cheng Shiau, William Tzu-Liang Chen, K. S. Clifford Chao

Published in: Cancer Immunology, Immunotherapy | Issue 4/2018

Abstract

Rectal cancer, which comprises 30% of all colorectal cancer cases, is one of the most common forms of cancer in the world. Patients with locally advanced rectal cancer (LARC) are often treated with neoadjuvant chemoradiotherapy (neoCRT) followed by surgery. However, after neoCRT treatment, approximately one-third of the patients progress to local recurrence or distant metastasis. In these studies, we found that patients with tumors that exhibited cytosolic HMGB1(Cyto-HMGB1) translocation and/or the presence of PD-1+ tumor-infiltrating lymphocytes (TILs) before treatment had a better clinical outcome. The better outcome is likely due to the release of HMGB1, which triggers the maturation of dendritic cells (DCs) via TLR4 activation, and the subsequent recruitment of PD-1+ tumor-infiltrating lymphocytes to the tumor site, where they participate in immune-scavenging. In conclusion, our results provide evidence that cyto-HMGB1 and/or PD-1+TIL are not only predictive biomarkers before treatment, but they can also potentially designate patients for personalized oncological management including immunotherapy.

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96. https://doi.org/10.3322/CA.2007.0010 CrossRefPubMed

Conde-Muino R, Cuadros M, Zambudio N, Segura-Jimenez I, Cano C, Palma P (2015) Predictive biomarkers to chemoradiation in locally advanced rectal cancer. Biomed Res Int 2015:921435. https://doi.org/10.1155/2015/921435

Yoon WH, Kim HJ, Kim CH, Joo JK, Kim YJ, Kim HR (2015) Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer. Ann Surg Treat Res 88(1):15–20. https://doi.org/10.4174/astr.2015.88.1.15 CrossRefPubMed

Balko JM, Black EP (2009) A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 9:145. https://doi.org/10.1186/1471-2407-9-145 CrossRefPubMedPubMedCentral

Palma P, Conde-Muino R, Rodriguez-Fernandez A, Segura-Jimenez I, Sanchez-Sanchez R, Martin-Cano J, Gomez-Rio M, Ferron JA, Llamas-Elvira JM (2010) The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol 5:119. https://doi.org/10.1186/1748-717X-5-119 CrossRefPubMedPubMedCentral

Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105(1):93–103. https://doi.org/10.1038/bjc.2011.189 CrossRefPubMedPubMedCentral

Teng F, Mu D, Meng X, Kong L, Zhu H, Liu S, Zhang J, Yu J (2015) Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res 5(6):2064–2074PubMedPubMedCentral

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139 CrossRefPubMed

Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71(17):5601–5605. https://doi.org/10.1158/0008-5472.CAN-11-1316 CrossRefPubMed

10.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25(3):611–618. https://doi.org/10.1093/annonc/mdt556 CrossRefPubMedPubMedCentral

11.

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666. https://doi.org/10.1056/NEJMoa051424 CrossRefPubMed

12.

Ohtani H (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7:4PubMedPubMedCentral

13.

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35):5944–5951. https://doi.org/10.1200/JCO.2008.19.6147 CrossRefPubMed

14.

Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71(17):5670–5677. https://doi.org/10.1158/0008-5472.CAN-11-0268 CrossRefPubMed

15.

Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G (2008) Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20(5):504–511. https://doi.org/10.1016/j.coi.2008.05.007 CrossRefPubMed

16.

Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H (2009) Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76(4):155–162. https://doi.org/10.1159/000218331 CrossRefPubMed

17.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059. https://doi.org/10.1038/nm1622 CrossRefPubMed

18.

Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Putter C, Wild CA, Schuler PJ, Greve J, Hoffmann TK, Lang S, Scherag A, Lehnerdt GF (2011) Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 9:139. https://doi.org/10.1186/1479-5876-9-139 CrossRefPubMedPubMedCentral

19.

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482–491. https://doi.org/10.1038/onc.2009.356 CrossRefPubMed

20.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331 CrossRefPubMed

21.

Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E (2009) High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27(9):1470–1476. https://doi.org/10.1200/JCO.2008.18.0513 CrossRefPubMed

22.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690 CrossRefPubMedPubMedCentral

23.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

24.

Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC (2010) Selection of CD8 + PD-1 + lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother 33(9):956–964. https://doi.org/10.1097/CJI.0b013e3181fad2b0 CrossRefPubMedPubMedCentral

25.

Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA (2014) PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124(5):2246–2259. https://doi.org/10.1172/JCI73639 CrossRefPubMedPubMedCentral

26.

Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu C-Y, Chang GJ (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30(15):1770–1776. https://doi.org/10.1200/jco.2011.39.7901 CrossRefPubMedPubMedCentral

27.

Lee H, Song M, Shin N, Shin CH, Min BS, Kim HS, Yoo JS, Kim H (2012) Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7(4):e34318. https://doi.org/10.1371/journal.pone.0034318 CrossRefPubMedPubMedCentral

28.

Fedchenko N, Reifenrath J (2014) Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue—a review. Diagn Pathol 9:221. https://doi.org/10.1186/s13000-014-0221-9 CrossRefPubMedPubMedCentral

29.

Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688–8696. https://doi.org/10.1200/JCO.2005.02.1329 CrossRefPubMed

30.

Clifford Chao KS, Ke WT-LC,Tao-Wei, Chiang S-F, Chen T-W, Huang C-Y, You Y-S, Yuh-Cherng Kuo (2016) Acquired immunity trumps ypN + and TRG as the sole prognostic biomarker for locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation therapy (NeoCRT). Int J Radiat Oncol Biol Phys 96(2S):S108. https://doi.org/10.1016/j.ijrobp.2016.06.265 (Abstract)CrossRef

31.

Kono K, Mimura K (2013) Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting. Oncoimmunology 2(1):e22197. https://doi.org/10.4161/onci.22197 CrossRefPubMedPubMedCentral

32.

Ueda M, Takahashi Y, Shinden Y, Sakimura S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K (2014) Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res 34(10):5357–5362PubMed

33.

Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L (2015) Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 21(10):1128–1138. https://doi.org/10.1038/nm.3944 CrossRefPubMed

34.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72. https://doi.org/10.1146/annurev-immunol-032712-100008 CrossRefPubMed

35.

Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5(8):825–830. https://doi.org/10.1038/sj.embor.7400205 CrossRefPubMedPubMedCentral

36.

Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N (2004) High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173(1):307–313CrossRefPubMed

37.

Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22(20):5551–5560. https://doi.org/10.1093/emboj/cdg516 CrossRefPubMedPubMedCentral

38.

Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, Robinson M, Van Zoelen MA, Yang H, Li J, Erlandsson-Harris H, Chavan SS, Wang H, Andersson U, Tracey KJ (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci USA 111(8):3068–3073. https://doi.org/10.1073/pnas.1316925111 CrossRefPubMedPubMedCentral

39.

Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R (2013) Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest 43(3):286–291. https://doi.org/10.1111/eci.12043 CrossRefPubMed

40.

Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R (2016) Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med 5(9):2350–2358. https://doi.org/10.1002/cam4.827 CrossRefPubMedPubMedCentral

41.

Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T, Kono K (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72(16):3967–3976. https://doi.org/10.1158/0008-5472.CAN-12-0851 CrossRefPubMed

42.

Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L (2008) Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 68(11):4026–4030. https://doi.org/10.1158/0008-5472.CAN-08-0427 CrossRefPubMed

43.

Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G (2009) Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14(4):364–375. https://doi.org/10.1007/s10495-008-0303-9 CrossRefPubMed

44.

Choi CH, Kim WD, Lee SJ, Park WY (2012) Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer. Radiat Oncol J 30(3):99–107. https://doi.org/10.3857/roj.2012.30.3.99 CrossRefPubMedPubMedCentral

45.

Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548. https://doi.org/10.1146/annurev.immunol.23.021704.115611 CrossRefPubMed

46.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119(2):317–327. https://doi.org/10.1002/ijc.21775 CrossRefPubMed

47.

Lee HJ, Kim A, Song IH, Park IA, Yu JH, Ahn JH, Gong G (2016) Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer. Pathol Int 66(4):202–209. https://doi.org/10.1111/pin.12393 CrossRefPubMed

Title: Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy
Authors: Chih-Yang Huang
Shu-Fen Chiang
Tao-Wei Ke
Tsung-Wei Chen
Yu-Ching Lan
Ying-Shu You
An-Cheng Shiau
William Tzu-Liang Chen
K. S. Clifford Chao
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 4/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2109-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice

Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors

Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras

Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer